

## Inflammatix

### *Inflammatix Biomarkers*

Today, 70% of inpatients with infections cannot be rapidly diagnosed by current methods, which only look directly for pathogens. This diagnostic uncertainty, coupled with the lack of tools for profiling the immune response, means that most antibiotics are given to patients who don't need them, leading directly to antimicrobial resistance. Inflammatix has developed a statistically rigorous, extensively validated diagnostic that 'reads' the immune system to determine presence and type of infection in any patient. Unlike prior attempts at host-response biomarkers that failed due to the heterogeneity of the syndrome, the Inflammatix biomarkers were discovered and validated across 24 cohorts, thus integrating information from the full spectrum of disease. An independent editorial in *Critical Care Medicine* wrote, "[The Inflammatix biomarkers] appear sufficiently robust to maintain predictive ability across a variety of different clinical conditions using a number of different platforms". Inflammatix is now operationalizing our biomarkers into a point-of-care diagnostic, with a rapid turnaround time.